Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $215.00 at Cantor Fitzgerald

Neurocrine Biosciences (NASDAQ:NBIX) had its target price hoisted by stock analysts at Cantor Fitzgerald from $210.00 to $215.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 28.69% from the stock’s current price.

Several other equities analysts have also weighed in on NBIX. Piper Sandler raised their target price on Neurocrine Biosciences from $207.00 to $210.00 and gave the company an “overweight” rating in a report on Friday. Zacks Research upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Leerink Partners increased their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. HC Wainwright raised their price objective on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. Finally, JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $198.23.

Neurocrine Biosciences Price Performance

Shares of NBIX stock traded down $18.43 on Friday, hitting $167.06. The company’s stock had a trading volume of 1,415,500 shares, compared to its average volume of 1,179,980. The stock has a market capitalization of $16.80 billion, a price-to-earnings ratio of 25.69, a P/E/G ratio of 0.76 and a beta of 0.39. Neurocrine Biosciences has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The firm’s fifty day moving average price is $167.61 and its 200-day moving average price is $146.25.

Insider Transactions at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 245,088 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total value of $37,824,431.04. Following the sale, the director directly owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. This trade represents a 32.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $160.25, for a total value of $1,762,750.00. Following the completion of the sale, the insider directly owned 25,846 shares in the company, valued at approximately $4,141,821.50. This represents a 29.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 395,422 shares of company stock worth $62,448,693. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Several large investors have recently made changes to their positions in NBIX. Generali Investments Management Co LLC grew its holdings in Neurocrine Biosciences by 19.8% in the 2nd quarter. Generali Investments Management Co LLC now owns 10,644 shares of the company’s stock valued at $1,794,000 after buying an additional 1,762 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Neurocrine Biosciences by 9.6% in the second quarter. Handelsbanken Fonder AB now owns 205,871 shares of the company’s stock valued at $34,696,000 after acquiring an additional 18,004 shares during the period. Fulton Bank N.A. boosted its position in shares of Neurocrine Biosciences by 5.2% in the second quarter. Fulton Bank N.A. now owns 4,895 shares of the company’s stock valued at $825,000 after acquiring an additional 243 shares during the period. Valeo Financial Advisors LLC acquired a new stake in shares of Neurocrine Biosciences in the second quarter worth $283,000. Finally, Trust Point Inc. acquired a new stake in shares of Neurocrine Biosciences in the second quarter worth $245,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Q2 results exceeded expectations. Neurocrine reported adjusted earnings of $2.85 per share, above the $2.26 Zacks consensus estimate, while revenue reached $959 million versus analysts’ $891 million forecast. Revenue increased approximately 39% year over year. Neurocrine Biosciences Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised full-year INGREZZA guidance. 2026 net product sales guidance for INGREZZA was increased to $2.825 billion-$2.875 billion. Second-quarter INGREZZA sales rose 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million following the Soleno Therapeutics acquisition. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Needham increased its price target. Needham & Company raised its target from $200 to $204 and maintained a “Buy” rating, signaling continued confidence in NBIX’s earnings growth and commercial outlook. Benzinga
• Neutral Sentiment: Analyst sentiment remains favorable. NBIX carries a consensus “Moderate Buy” rating and an average price target of approximately $194, although investors may be looking for additional upside after the stock’s recent strength.
• Negative Sentiment: A director sold shares. Leslie Norwalk sold 1,250 shares worth approximately $227,513, reducing her holdings by 44%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal. SEC insider transaction filing

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.